Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 7/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863358 | 0.90 | SIRT5 (0.52) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL21097237 | 0.88 | PSMB8 (0.49) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL18774075 | 0.86 | SIRT2 (0.50) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL18752309 | 0.85 | SIRT2 (0.49) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL12285322 | 0.81 | SIRT2 (0.49) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL25863476 | 0.81 | PSMB5 (0.44) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL17750718 | 0.81 | SIRT5 (0.57) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL17039855 | 0.81 | SIRT5 (0.57) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL17039859 | 0.80 | SIRT5 (0.56) | SIRT5SIRT1PSMB8PSMB9PSMB5 | |
| SCHEMBL17750717 | 0.80 | SIRT5 (0.56) | SIRT5SIRT1PSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20190184025-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190184025-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | SIRT5 4536/4885SIRT1 4761/4885PSMB8 4130/4885 |
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | SIRT5 4536/4885SIRT1 4761/4885PSMB8 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.